GTECH S Sample Clauses

GTECH S p.A., a company incorporated in Italy as a società per azioni (“GTECH”);
AutoNDA by SimpleDocs
GTECH S. P.A. as Parent and Original Borrower GTECH CORPORATION as Original Guarantor BNP PARIBAS, ITALIAN BRANCH as Mandated Lead Arranger and Original International Lender UNICREDIT BANK AG, MILAN BRANCH as Mandated Lead Arranger and Original International Lender INTESA SANPAOLO S.P.A. as Original Italian Lender 29 January 2015 Dear Sirs, €800,000,000 Facilities Agreement for GTECH S.p.A. Reference is made to your letter dated 29 January 2015, pursuant to which you proposed to our Company the execution of the €800,000,000 facilities agreement for GTECH S.p.A. (the “Facilities Agreement”). We hereby notify you of our acceptance of the Facilities Agreement and we attach in the Annex hereto the Facilities Agreement. Yours sincerely Xxxxxxx Xxxxxxx and Xxxxxxx Xxxxxxxx
GTECH S. P.A. as Parent and Original Borrower GTECH CORPORATION as Original Guarantor BNP PARIBAS, ITALIAN BRANCH as Mandated Lead Arranger and Original International Lender BANCA IMI S.P.A. as Mandated Lead Arranger INTESA SANPAOLO S.P.A. as Original Italian Lender 29 January 2015 Dear Sirs, €800,000,000 Facilities Agreement for GTECH S.p.A. Reference is made to your letter dated 29 January 2015, pursuant to which you proposed to our Company the execution of the €800,000,000 facilities agreement for GTECH S.p.A. (the “Facilities Agreement”). We hereby notify you of our acceptance of the Facilities Agreement and we attach in the Annex hereto the Facilities Agreement. Yours sincerely /s/ Xxxxxx Xxxxx and Xxxxxxxx Xxxxxxx UNICREDIT BANK AG, MILAN BRANCH as Mandated Lead Arranger and Original International Lender ANNEX To:
GTECH S. P.A. as Parent and Original Borrower GTECH CORPORATION as Original Guarantor BNP PARIBAS, ITALIAN BRANCH as Mandated Lead Arranger and Original International Lender BANCA IMI S.P.A. as Mandated Lead Arranger UNICREDIT BANK AG, MILAN BRANCH as Mandated Lead Arranger and Original International Lender 29 January 2015 Dear Sirs, €800,000,000 Facilities Agreement for GTECH S.p.A. Reference is made to your letter dated 29 January 2015, pursuant to which you proposed to our Company the execution of the €800,000,000 facilities agreement for GTECH S.p.A. (the “Facilities Agreement”). We hereby notify you of our acceptance of the Facilities Agreement and we attach in the Annex hereto the Facilities Agreement. Yours sincerely /s/ Xxxx Xxxxxxxxx INTESA SANPAOLO S.P.A. as Original Italian Lender ANNEX XXXXXXXX CHANCE STUDIO LEGALE IN ASSOCIAZIONE CON XXXXXXXX CHANCE GTECH S.P.A. AS PARENT GTECH S.P.A. AS ORIGINAL BORROWER GTECH CORPORATION AS ORIGINAL GUARANTOR BNP PARIBAS, ITALIAN BRANCH BANCA IMI S.P.A. MEDIOBANCA — BANCA DI CREDITO FINANZIARIO S.P.A. UNICREDIT BANK AG, MILAN BRANCH AS MANDATED LEAD ARRANGERS AND BNP PARIBAS, ITALIAN BRANCH INTESA SANPAOLO S.P.A. MEDIOBANCA — BANCA DI CREDITO FINANZIARIO S.P.A. UNICREDIT BANK AG, MILAN BRANCH AS ORIGINAL LENDERS MEDIOBANCA — BANCA DI CREDITO FINANZIARIO S.P.A. AS AGENT €800,000,000 TERM LOAN FACILITIES FOR GTECH S.P.A. CONTENTS Clause Page

Related to GTECH S

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • VOETSTOOTS The PROPERTY is sold:

  • Přetrvávající platnost Tento odstavec 1.3 “Zdravotní záznamy a Studijní data a údaje” zůstane závazný i v případě zániku platnosti či vypršení platnosti této Smlouvy.

  • Přetrvající platnost This Section 3 “

  • COVID-19 Residents acknowledge that in March 2020 the World Health Organization declared a global pandemic of the virus leading to COVID-19. The Governments of Canada, the Province of Ontario, and local Governments responded to the pandemic with legislative amendments, controls, orders, by-laws, requests of the public, and requests and requirements to Humber (collectively, the “Directives”). It is uncertain how long the pandemic, and the related Directives, will continue, and it is unknown whether there may be a resurgence of the virus leading to COVID-19 or any mutation thereof (collectively, “COVID- 19”). Without limiting the generality of the foregoing paragraph, Humber shall not be held legally responsible or be deemed to be in breach of this Agreement for any damages or loss arising out of or caused by:

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Exportbepalingen Het is u niet toegestaan de Apple software te gebruiken of anderszins te exporteren of te herexporteren, behalve voor zover toegestaan krachtens de wetten van de Verenigde Staten en van het rechtsgebied waarin u de Apple software hebt verkregen. In het bijzonder, maar zonder beperking, is het u niet toegestaan de Apple software te exporteren of te herexporteren (a) naar een land waarvoor door de Verenigde Staten een embargo is ingesteld of (b) naar enige persoon die voorkomt op de door het U.S. Treasury Department samengestelde lijst van "Specially Designated Nationals" of op de door het U.S. Department of Commerce samengestelde "Denied Person’s List" of "Entity List". Door de Apple software te gebruiken, verklaart u dat u zich niet bevindt in een dergelijk land of op een van de bovengenoemde lijsten voorkomt. U verklaart tevens dat u de Apple software niet zult gebruiken voor doeleinden die verboden zijn volgens de wetten van de Verenigde Staten met inbegrip van, maar niet beperkt tot, de ontwikkeling, het ontwerp, de fabricage of productie van raketten, nucleaire, chemische of biologische wapens.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

Time is Money Join Law Insider Premium to draft better contracts faster.